Active, not recruitingPhase 3NCT04810078

A Study of Subcutaneous Nivolumab Versus Intravenous Nivolumab in Participants With Previously Treated Clear Cell Renal Cell Carcinoma That is Advanced or Has Spread

Studying Clear cell renal carcinoma

Last synced from ClinicalTrials.gov May 6, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Bristol-Myers Squibb
Principal Investigator: Bristol-Myers Squibb
Bristol-Myers Squibb
Intervention: Nivolumab and rHuPH20(biological)
Enrollment: 681 enrolled
Eligibility: 18 years · All sexes
Timeline: 2021 – 2027

Study locations (30)

Local Institution, Chicago, Illinois, United States
Local Institution - 0025, Buffalo, New York, United States
Local Institution - 0088, West Reading, Pennsylvania, United States
Local Institution - 0095, Capital Federal, Buenos Aires, Argentina
Local Institution - 0058, Mar del Plata, Buenos Aires, Argentina
Local Institution - 0037, Pergamino, Buenos Aires, Argentina
Local Institution - 0079, Parana, Córdoba Province, Argentina
Local Institution - 0030, Río Cuarto, Córdoba Province, Argentina
Local Institution - 0066, Viedma, Río Negro Province, Argentina
Local Institution - 0038, Buenos Aires, Argentina
Local Institution - 0056, San Juan, Argentina
Local Institution - 0064, Curitiba, Paraná, Brazil
Local Institution - 0107, Ijuí, Rio Grande do Sul, Brazil
Local Institution - 0039, Porto Alegre, Rio Grande do Sul, Brazil
Local Institution - 0071, Barretos, São Paulo, Brazil
+15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04810078 on ClinicalTrials.gov

Other trials for Clear cell renal carcinoma

Additional recruiting or active studies for the same condition.

See all trials for Clear cell renal carcinoma →

← Back to all trials